SI2285364T1 - Terapevtska regeneracija in obogatitev lubrikacije okularne površine - Google Patents

Terapevtska regeneracija in obogatitev lubrikacije okularne površine

Info

Publication number
SI2285364T1
SI2285364T1 SI200931129T SI200931129T SI2285364T1 SI 2285364 T1 SI2285364 T1 SI 2285364T1 SI 200931129 T SI200931129 T SI 200931129T SI 200931129 T SI200931129 T SI 200931129T SI 2285364 T1 SI2285364 T1 SI 2285364T1
Authority
SI
Slovenia
Prior art keywords
enrichment
ocular surface
surface lubrication
replenishment
therapeutic
Prior art date
Application number
SI200931129T
Other languages
English (en)
Slovenian (sl)
Inventor
Benjamin Sullivan
Tannin A. Schmidt
David A. Sullivan
Original Assignee
The Regents Of The University Of California
Schepens Eye Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California, Schepens Eye Research Institute filed Critical The Regents Of The University Of California
Publication of SI2285364T1 publication Critical patent/SI2285364T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Eyeglasses (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SI200931129T 2008-05-07 2009-04-08 Terapevtska regeneracija in obogatitev lubrikacije okularne površine SI2285364T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5111208P 2008-05-07 2008-05-07
EP09743204.1A EP2285364B1 (en) 2008-05-07 2009-04-08 Therapeutic replenishment and enrichment of ocular surface lubrication
PCT/US2009/039887 WO2009137217A2 (en) 2008-05-07 2009-04-08 Therapeutic replenishment and enrichment of ocular surface lubrication

Publications (1)

Publication Number Publication Date
SI2285364T1 true SI2285364T1 (sl) 2015-03-31

Family

ID=41264988

Family Applications (3)

Application Number Title Priority Date Filing Date
SI200931129T SI2285364T1 (sl) 2008-05-07 2009-04-08 Terapevtska regeneracija in obogatitev lubrikacije okularne površine
SI200931699T SI2915529T1 (sl) 2008-05-07 2009-04-08 Terapevtska regeneracija in obogatitev lubrikacije okularne površine
SI200932001T SI2276496T1 (sl) 2008-05-07 2009-05-06 Terapevtska modulacija mazanja očesne površine

Family Applications After (2)

Application Number Title Priority Date Filing Date
SI200931699T SI2915529T1 (sl) 2008-05-07 2009-04-08 Terapevtska regeneracija in obogatitev lubrikacije okularne površine
SI200932001T SI2276496T1 (sl) 2008-05-07 2009-05-06 Terapevtska modulacija mazanja očesne površine

Country Status (16)

Country Link
US (9) US9138457B2 (cg-RX-API-DMAC10.html)
EP (4) EP2915529B1 (cg-RX-API-DMAC10.html)
JP (3) JP5508398B2 (cg-RX-API-DMAC10.html)
CN (2) CN102164593B (cg-RX-API-DMAC10.html)
CA (3) CA2722913C (cg-RX-API-DMAC10.html)
CY (2) CY1119122T1 (cg-RX-API-DMAC10.html)
DK (3) DK2285364T3 (cg-RX-API-DMAC10.html)
ES (3) ES2633792T3 (cg-RX-API-DMAC10.html)
HR (3) HRP20150097T1 (cg-RX-API-DMAC10.html)
HU (2) HUE024146T2 (cg-RX-API-DMAC10.html)
LT (2) LT2915529T (cg-RX-API-DMAC10.html)
PL (3) PL2915529T3 (cg-RX-API-DMAC10.html)
PT (2) PT2285364E (cg-RX-API-DMAC10.html)
RU (1) RU2510274C2 (cg-RX-API-DMAC10.html)
SI (3) SI2285364T1 (cg-RX-API-DMAC10.html)
WO (3) WO2009137217A2 (cg-RX-API-DMAC10.html)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US7981145B2 (en) 2005-07-18 2011-07-19 Tearscience Inc. Treatment of meibomian glands
US8950405B2 (en) 2006-05-15 2015-02-10 Tearscience, Inc. Treatment of obstructive disorders of the eye or eyelid
US20070060988A1 (en) 2005-07-18 2007-03-15 Grenon Stephen M Melting meibomian gland obstructions
US7981146B2 (en) 2006-05-15 2011-07-19 Tearscience Inc. Inner eyelid treatment for treating meibomian gland dysfunction
WO2013003594A2 (en) 2011-06-28 2013-01-03 Tearscience, Inc. Methods and systems for treating meibomian gland dysfunction using radio-frequency energy
US8083787B2 (en) 2005-07-18 2011-12-27 Tearscience, Inc. Method and apparatus for treating meibomian gland dysfunction
US20080114423A1 (en) 2006-05-15 2008-05-15 Grenon Stephen M Apparatus for inner eyelid treatment of meibomian gland dysfunction
US7981095B2 (en) 2005-07-18 2011-07-19 Tearscience, Inc. Methods for treating meibomian gland dysfunction employing fluid jet
US20090043365A1 (en) * 2005-07-18 2009-02-12 Kolis Scientific, Inc. Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8128673B2 (en) 2006-05-15 2012-03-06 Tearscience, Inc. System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US7981147B2 (en) 2006-05-15 2011-07-19 Tearscience, Inc. Outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US7976573B2 (en) 2006-05-15 2011-07-12 Tearscience, Inc. Inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8137390B2 (en) 2006-05-15 2012-03-20 Tearscience, Inc. System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction
US9314369B2 (en) 2006-05-15 2016-04-19 Tearscience, Inc. System for inner eyelid treatment of meibomian gland dysfunction
US8128674B2 (en) 2006-05-15 2012-03-06 Tearscience, Inc. System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8007524B2 (en) 2006-05-15 2011-08-30 Tearscience, Inc. Heat treatment and heat loss reduction for treating meibomian gland dysfunction
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
US8506944B2 (en) 2008-05-07 2013-08-13 The Regents Of The University Of California Replenishment and enrichment of ocular surface lubrication
HRP20150097T1 (hr) 2008-05-07 2015-03-27 The Regents Of The University Of California Terapijska nadopuna i poboljšanje vlaženja površine oka
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
WO2010135736A2 (en) 2009-05-22 2010-11-25 Singularis Inc. Application and uses of prg4 and therapeutic modulation thereof
US8791158B2 (en) 2010-01-11 2014-07-29 Gtx, Inc. Methods of treating meibomian gland dysfunction
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
AU2010362444B2 (en) 2010-10-14 2015-08-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2012174123A1 (en) * 2011-06-13 2012-12-20 Allergan, Inc. Treatment of psychological trauma
KR20140054005A (ko) * 2011-06-29 2014-05-08 알러간, 인코포레이티드 마크로골 15 하이드록시스테아레이트 제형
US20130029919A1 (en) * 2011-07-26 2013-01-31 Allergan, Inc. Two part formulation system for opthalmic delivery
WO2013079213A1 (en) * 2011-11-30 2013-06-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of dry eye syndrome
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
US9827250B2 (en) * 2012-07-31 2017-11-28 Johnson & Johnson Vision Care, Inc. Lens incorporating myopia control optics and muscarinic agents
US10842670B2 (en) 2012-08-22 2020-11-24 Johnson & Johnson Vision Care, Inc. Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices
US9763827B2 (en) 2013-04-30 2017-09-19 Tear Film Innovations, Inc. Systems and methods for the treatment of eye conditions
WO2014179356A1 (en) 2013-04-30 2014-11-06 Tear Film Innovations Llc Systems and methods for the treatment of eye conditions
EA201501080A1 (ru) 2013-06-26 2016-07-29 Ксижен Инфлемейшн Лтд. Новое применение обладающих способностью проникать в клетку пептидных ингибиторов пути трансдукции сигнала jnk для лечения различных заболеваний
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
US9982027B2 (en) 2013-10-22 2018-05-29 Lubris Llc Control of rheological properties of mixed hyaluronate/lubricin solutions
US9668916B2 (en) 2013-11-04 2017-06-06 Vance M. Thompson Conjunctival cover and methods therefor
US20150141328A1 (en) * 2013-11-18 2015-05-21 The Schepens Eye Research Institute Stimulation of human meibomian gland function
US10500250B2 (en) 2013-11-26 2019-12-10 Lubris Llc Compositions and methods for inhibiting intercellular interactions
CA2950535C (en) * 2014-06-15 2023-03-28 Yeda Research And Development Co. Ltd. Surface treatment by water-soluble polymers and lipids/liposomes
IL234929B (en) * 2014-10-01 2021-01-31 Yeda Res & Dev Liposomes-containing antifouling compositions and uses thereof
US9395557B2 (en) 2014-11-12 2016-07-19 Vance M. Thompson Partial corneal conjunctival contact lens
AU2016211694B2 (en) 2015-01-26 2021-11-11 Lubris Llc Use of PRG4 as an anti-inflammatory agent
US9869883B2 (en) 2015-03-11 2018-01-16 Vance M. Thompson Tear shaping for refractive correction
AU2016240948A1 (en) * 2015-04-03 2017-11-16 Santen Pharmaceutical Co., Ltd. Dry eye therapeutic agent having as active ingredient nandrolone or ester thereof or methenolone or ester thereof
LT3300482T (lt) * 2015-05-19 2021-10-25 Lubris Llc Prg4 panaudojimas dinaminio regos aštrumo pagerinimui ir aukštesnės eilės aberacijų sumažinimui
JP6718608B2 (ja) * 2016-05-25 2020-07-08 国立大学法人愛媛大学 眼表面・眼瞼摩擦係数測定装置および眼表面・眼瞼摩擦係数評価方法
US10974063B2 (en) 2016-06-30 2021-04-13 Alcon Inc. Light therapy for eyelash growth
US10353220B2 (en) 2016-10-17 2019-07-16 Vance M. Thompson Tear shaping for refractive correction
US10678067B2 (en) 2018-04-06 2020-06-09 Vance M. Thompson Tear shaping for refractive correction
WO2019246522A1 (en) * 2018-06-21 2019-12-26 Lubris Llc Lubricin for use in wound healing
US20220008518A1 (en) * 2018-11-08 2022-01-13 The Schepens Eye Research Institute, Inc. Therapeutic approaches for tissue reconstruction and wound healing treatment
WO2020130147A1 (ja) 2018-12-21 2020-06-25 国立大学法人京都大学 ルブリシン局在軟骨様組織、その製造方法及びそれを含む関節軟骨損傷治療用組成物
JP7667569B2 (ja) * 2019-01-15 2025-04-23 コーネル ユニバーシティー 組換えラブリシン、並びにそれを使用するための組成物及び方法
EP4003225A4 (en) * 2019-07-26 2023-05-31 Pandorum Technologies Private Limited BIOLOGICAL INK FORMULATIONS, BIO-PRINTED LENTICULUS AND RELATED APPLICATIONS
WO2021067823A2 (en) * 2019-10-05 2021-04-08 The Schepens Eye Research Institute, Inc. A new treatment for meibomian gland dysfunction
US11609438B2 (en) * 2019-10-31 2023-03-21 Menicon Singapore Pte Ltd. Ocular lens with friction control structures
KR20220145361A (ko) * 2020-02-24 2022-10-28 노파르티스 아게 재조합적으로 생성된 폴리펩타이드의 정제

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550022A (en) * 1981-10-05 1985-10-29 Alcon Laboratories, Inc. Tissue irrigating solution
SE8501723L (sv) 1985-04-09 1986-10-10 Pharmacia Ab Preparation att anvendas vid behandling av ledinflammation
US4964206A (en) * 1988-03-15 1990-10-23 Minnesota Mining And Manufacturing Company Intraocular lens anchoring filament to lens element fixation method
US4964205A (en) * 1988-06-13 1990-10-23 Rampart Packaging Inc. Method for making screw cap jar
US6433142B1 (en) 1989-08-08 2002-08-13 Genetics Institute, Llc Megakaryocyte stimulating factors
US5326558A (en) 1989-08-08 1994-07-05 Genetics Institute, Inc. Megakaryocytopoietic factor
RU2033165C1 (ru) 1989-10-13 1995-04-20 Межотраслевой научно-технический комплекс "Микрохирургия глаза" Способ получения пластичного материала из коллагена
US5688765A (en) 1992-04-21 1997-11-18 The Schepens Eye Research Institute, Inc. Ocular therapy in Sjogren's syndrome using topically applied androgensor TGF-β
US6107289A (en) * 1992-04-21 2000-08-22 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β
JPH07508716A (ja) 1992-04-21 1995-09-28 ザ　スキーペンズ　アイ　リサーチ　インスティテュート，インコーポレイテッド シェーグレン症候群における眼のアンドロゲン療法
IL106922A (en) * 1992-09-14 1998-08-16 Novartis Ag Composite materials with one or more wettable surfaces and process for their preparation
US5351100A (en) * 1992-12-09 1994-09-27 Bmc Industries, Inc. Glass multifocal ophthalmic lens with polarizing element and method of making
DE69434617D1 (de) 1993-11-19 2006-04-06 Univ Sydney Verfahren zur prophylaxe oder kontrolle des katarakts
US5515590A (en) * 1994-07-19 1996-05-14 University Of Kentucky Research Foundation Method for reducing the generation of wear particulates from an implant
US5518732A (en) * 1995-02-14 1996-05-21 Chiron Vision, Inc. Bio-erodible ophthalmic shield
DE69629230D1 (de) * 1995-03-24 2003-09-04 Ocular Res Of Bonton Inc Hydrogellinse mit Lipid-Vorbeschichtigung
RU2207885C2 (ru) * 1995-08-30 2003-07-10 Фармация Аб Способ подачи небольшого объема лечебного раствора к целевому месту
US6689748B1 (en) * 1998-04-08 2004-02-10 Theoharis C. Theoharides Method of treating mast cell activation-induced diseases with a proteoglycan
AU1521000A (en) * 1998-11-06 2000-05-29 Schepens Eye Research Institute, Inc., The Local use of soluble tumor necrosis receptor i (stnfri) for prophylaxis and treatment of corneal transplant rejection and other disorders of the eye
JP4551563B2 (ja) * 1998-11-10 2010-09-29 電気化学工業株式会社 ヒアルロン酸ゲルの製造方法及び医用材料
US6743774B1 (en) 1999-04-23 2004-06-01 Rhode Island Hospital Tribonectins
US6960562B2 (en) 1999-04-23 2005-11-01 Rhode Island Hospital, A Lifespan Partner Tribonectin polypeptides and uses thereof
NZ521079A (en) * 2000-02-03 2004-08-27 Denki Kagaku Kogyo Kk Hyaluronic acid gel, process for producing the same, and medical material containing the same
US7026500B2 (en) * 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
AU3960102A (en) * 2000-12-20 2002-07-01 Alcon Universal Ltd Intraocular irrigating solution having improved flow characteristics
WO2002049611A2 (en) * 2000-12-20 2002-06-27 Alcon, Inc. Ophthalmic lubricating solution adapted for use in lasik surgery
AU2002249046A1 (en) * 2001-04-23 2002-11-05 Nucryst Pharmaceuticals Corp. Lubricious coatings for substrates
US6815074B2 (en) * 2001-05-30 2004-11-09 Novartis Ag Polymeric materials for making contact lenses
CN1980582B (zh) 2001-08-17 2010-12-22 美你康株式会社 用于用后即弃式软隐形眼镜的包装
US20030134810A1 (en) 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
TWI255224B (en) * 2002-01-09 2006-05-21 Novartis Ag Polymeric articles having a lubricious coating and method for making the same
TW200304385A (en) * 2002-03-13 2003-10-01 Novartis Ag Materials containing multiple layers of vesicles
SE0201479D0 (sv) * 2002-05-16 2002-05-16 Pharmacia Groningen Bv Kit and method in eye surgery
US20050196370A1 (en) 2003-03-18 2005-09-08 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
EP1651192A1 (en) 2003-08-06 2006-05-03 Nirmal Mulye Pharmaceutical composition containing water soluble drug
WO2005016130A2 (en) 2003-08-14 2005-02-24 Wyeth Recombinant lubricin molecules and uses thereof
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
WO2005027933A1 (en) 2003-09-23 2005-03-31 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Unsaturated phosphatidylcholines and uses thereof
CA2558497A1 (en) * 2004-03-05 2005-09-15 Synthes (U.S.A.) Use of a mixture for the production of an agent for treating defective or degenerated cartilage in the production of natural cartilage replacement in vitro
US20090060933A1 (en) 2004-06-14 2009-03-05 Estell David A Proteases producing an altered immunogenic response and methods of making and using the same
US20050287223A1 (en) * 2004-06-23 2005-12-29 Peyman Gholam A Use of amniotic membrane as biocompatible devices
WO2006088491A2 (en) * 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
US20080287369A1 (en) * 2004-07-23 2008-11-20 Jay Gregory D Compositions and Methods for Viscosupplementation
US7662509B2 (en) * 2004-10-29 2010-02-16 Medtronic, Inc. Lithium-ion battery
EP1858522A4 (en) * 2005-03-02 2008-07-16 Pharmaceutical Inc Nascent PHARMACEUTICALLY ACCEPTABLE CARRIER FOR OPHTHALMIC COMPOSITIONS
SI1881823T1 (sl) 2005-05-17 2015-04-30 Sarcode Bioscience Inc. Sestavki in postopki za zdravljenje bolezni oäśesa
US20080213274A1 (en) * 2005-10-28 2008-09-04 Sabbadini Roger A Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye
JP5549045B2 (ja) * 2006-01-13 2014-07-16 大正製薬株式会社 蒸発亢進型ドライアイの予防又は改善用水性点眼剤
US20080094573A1 (en) * 2006-04-04 2008-04-24 Vermette Patrick Surface-modified materials, such as contact lenses, methods and kits for their preparation, and uses thereof
US9539202B2 (en) * 2006-04-28 2017-01-10 Universidad Complutense De Madrid Formulation of liposomal vesicles in aqueous solutions with lachrymal film characteristics
US20070264226A1 (en) * 2006-05-10 2007-11-15 Karagoezian Hampar L Synergistically enhanced disinfecting solutions
AU2007287070C1 (en) * 2006-08-24 2013-02-14 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
US20080097606A1 (en) 2006-10-19 2008-04-24 Cragg Andrew H Knee joint prosthesis and hyaluronate compositions for treatment of osteoarthritis
US20080197324A1 (en) 2007-02-20 2008-08-21 Fang Zhao Ophthalmic composition containing a polyol-acid copolymer
US20090068247A1 (en) 2007-09-12 2009-03-12 Mucosal Therapeutics Biocompatible devices coated with a tribonectin and methods for their production
CN101903807B (zh) * 2007-12-20 2013-01-09 诺瓦提斯公司 隐形眼镜的制造方法
HRP20150097T1 (hr) * 2008-05-07 2015-03-27 The Regents Of The University Of California Terapijska nadopuna i poboljšanje vlaženja površine oka
US8506944B2 (en) 2008-05-07 2013-08-13 The Regents Of The University Of California Replenishment and enrichment of ocular surface lubrication

Also Published As

Publication number Publication date
US20160015780A1 (en) 2016-01-21
US9421241B2 (en) 2016-08-23
US20160101149A1 (en) 2016-04-14
SI2276496T1 (sl) 2019-11-29
JP5439652B2 (ja) 2014-03-12
HRP20171079T1 (hr) 2017-10-06
CY1119122T1 (el) 2018-02-14
JP2011519933A (ja) 2011-07-14
EP2285364A2 (en) 2011-02-23
HUE045686T2 (hu) 2020-01-28
WO2009137217A2 (en) 2009-11-12
WO2009137602A1 (en) 2009-11-12
US20160235809A1 (en) 2016-08-18
US20110142908A1 (en) 2011-06-16
PT2285364E (pt) 2015-02-24
PT2915529T (pt) 2017-07-24
WO2009137217A8 (en) 2010-12-09
EP2276496A4 (en) 2011-08-17
ES2633792T3 (es) 2017-09-25
JP2011519949A (ja) 2011-07-14
US9585936B2 (en) 2017-03-07
PL2915529T3 (pl) 2017-10-31
CY1122638T1 (el) 2021-03-12
RU2010147935A (ru) 2012-06-20
RU2510274C2 (ru) 2014-03-27
HRP20191732T1 (hr) 2019-12-13
JP2011520812A (ja) 2011-07-21
LT2276496T (lt) 2019-10-25
EP2276497A1 (en) 2011-01-26
ES2748139T3 (es) 2020-03-13
WO2009137603A1 (en) 2009-11-12
JP5474054B2 (ja) 2014-04-16
EP2276496B1 (en) 2019-07-10
SI2915529T1 (sl) 2017-09-29
US20180028598A1 (en) 2018-02-01
US8945604B2 (en) 2015-02-03
US20110059902A1 (en) 2011-03-10
US8563028B2 (en) 2013-10-22
JP5508398B2 (ja) 2014-05-28
CA2722913A1 (en) 2009-11-12
US9730978B2 (en) 2017-08-15
EP2285364A4 (en) 2011-07-20
ES2530723T3 (es) 2015-03-04
WO2009137217A3 (en) 2009-12-30
CN105664136A (zh) 2016-06-15
HRP20150097T1 (hr) 2015-03-27
CA2722913C (en) 2018-02-27
CA2723144C (en) 2018-05-22
US9393285B2 (en) 2016-07-19
US9248161B2 (en) 2016-02-02
LT2915529T (lt) 2018-10-25
EP2915529B1 (en) 2017-06-14
EP2285364B1 (en) 2015-01-21
EP2276496A1 (en) 2011-01-26
DK2285364T3 (en) 2015-02-16
PL2276496T3 (pl) 2020-01-31
HUE024146T2 (en) 2016-02-29
PL2285364T3 (pl) 2015-04-30
CN102164593B (zh) 2016-02-03
DK2915529T3 (en) 2017-08-07
US9138457B2 (en) 2015-09-22
CN102164593A (zh) 2011-08-24
CA2722944A1 (en) 2009-11-12
CA2723144A1 (en) 2009-11-12
DK2276496T3 (da) 2019-10-07
EP2276497A4 (en) 2011-12-21
US20140099343A1 (en) 2014-04-10
US20110070222A1 (en) 2011-03-24
EP2276497B1 (en) 2020-04-22
EP2915529A1 (en) 2015-09-09
US20140296159A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
PT2915529T (pt) Reposição e enriquecimento terapêutico de lubrificação da superficie ocular
ZA200901842B (en) Ocular devices and methods of making and using thereof
EP2369972A4 (en) METHODS AND DEVICES FOR CORRECTING EYE REFRACTION
EP2262450A4 (en) IMPLANTS AND METHODS OF USE
IL205977A0 (en) 5-anilinoimidazopyridines and methods of use
ZA201008483B (en) Diazacarbazoles and methods of use
IL213547A0 (en) Compounds and methods of use
GB0911580D0 (en) Use of one or more cannabinoids in the treatment of epilepsy
ZA201102076B (en) Herbicide-resistant ahas-mutants and methods of use
IL194189A0 (en) Combination treatment of metabolic disorders
ZA200905101B (en) Diagosis and treatment of preeclampsia
ZA201108960B (en) Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
EP2242854A4 (en) COMPOUNDS AND USES THEREOF
IL209548A0 (en) Diazacarbazoles and methods of use
EP2268281A4 (en) THIENOPYRROLES AND PYRROLOTHIAZOLES AS NEW THERAPEUTIC AGENTS
ZA200905741B (en) Indenoisoquinolinone analogs and methods of use thereof
ZA200901452B (en) Treatment of vertigo with acetyl-L-leucine
IL207127A0 (en) Aldh-2 inhibitors in the treatment of addiction
ZA201000225B (en) Treatment of depression
GB2451821B (en) Eye bath
PT2276496T (pt) Modulação terapêutica de lubrificação da superfície ocular.
GB0714430D0 (en) Disposable Eye Bath
GB0804122D0 (en) Treatment of raynaud's phenomenon
GB0601091D0 (en) The Treatment Of Ocular Conditions
HU0800757D0 (en) Method of examinating colour-blindness and visual acuity